Has The Time Arrived To Take a Serious Look At This Stock-LMRI

Acrobull Canada Advisory Inc.

April 22			2026
Name	Ticker	Sector/Industry		Market Cap	Risk Factor
Lumexa Imaging Holdings, Inc.	LMRI-NASDAQ	Medical Devices		$895.597 Million	Medium

Lumexa Imaging Holdings, Inc. is a healthcare company that owns and operates diagnostic imaging centers across the United States. It offers a range of outpatient imaging services, including MRI, CT, and PET scans, along with X-rays, ultrasounds, and mammography for both diagnostic and screening purposes. The company was established in 2018 and is headquartered in Raleigh, North Carolina.

Recent Highlights

Leadership expansion (April 2026): The company appointed a new Chief Growth Officer to drive expansion through acquisitions, partnerships, and new center development, strengthening its long-term growth strategy.

Record operational expansion (2025–2026): Lumexa opened a record 9 new imaging centers in 2025, bringing its network to 185+ locations across 13 states, significantly increasing its national footprint.

Financial Highlights

Lumexa Imaging Holdings, Inc. reported 2025 revenue of about $1.023 billion, reflecting roughly 7.8% year-over-year growth across its diagnostic imaging centers in the United States.

Adjusted EBITDA reached approximately $230.2 million in 2025, increasing around 14.6%, with margins in the 22–23% range, showing improving operational efficiency and scale benefits.

Despite growth, the company posted a net loss of about $47.1 million in 2025, an improvement compared with a larger loss of roughly $94.1 million in 2024.

In the fourth quarter of 2025, revenue totaled about $267.7 million, up around 7.9% year-over-year, while adjusted EBITDA was approximately $63.8 million, rising about 18.6%.

The company expanded operations by adding 10 new imaging centers in 2025 and continued reducing leverage, signaling ongoing investment and gradual financial strengthening despite remaining unprofitable.

Stock Observation- Lumexa Imaging Holdings, Inc. expects to build on its 2025 revenue of approximately $1.023 billion and 7.8% year-over-year growth by expanding its diagnostic imaging network, enhancing service offerings, and increasing patient volumes. The company anticipates that continued operational improvements, strategic partnerships, and geographic expansion will support sustained revenue growth and strengthen its overall market position in the coming years.

Risk Involved- Financial performance of the company may have an impact on the company stock performance.

Considering all the factors and financials of the company Acrobull Canada Advisory Inc. maintains Customer Choose Buy for the stock.

Disclaimer- Though our research is fundamentally and technically based on Acrobull Canada Advisory Inc. only provides general advice on the stocks and it is imperative for the investors to do the risk assessment for themselves before investing as Acrobull Canada Advisory Inc. would not be liable for any loss or profit arising out through the investment made by the investors on our recommendations.

It is also advisable for the investors to consult with Financial Advisor, Broker or to seek any legal assistance as the research conducted by Acrobull Canada Advisory Inc. Inc ltd. is factually based and recommendations are given in accordance with that, but it is imperative to understand that Acrobull Canada Advisory Inc. does not guarantee returns.

Acrobull Recommendation Based on Evaluation

Current Market Price	$9.32 USD
Acrobull Recommendation	Buy at 8.90 USD
Target Price	$10.45 USD
RSI Level	46 (Neutral)
Total Shares Outstanding	96.11 million
Shares held by Insiders Risk Factor Stop Loss	81.04% Medium 5%